<<< Full experiment listing


PXD017060 is an original dataset announced via ProteomeXchange.

Dataset Summary
TitleN-Glycosylation of the Epidermal Growth Factor Receptor (EGFR) Derived from Human Oral Squamous Carcinoma Cells with beta-Catenin/CREB-Binding Protein (CBP) Inhibition
DescriptionHead and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy in the world; oral squamous cell carcinomas (OSCC) account for the majority of HNSCC cases. A major driver of OSCC is the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK) with 12 N-glycosylation sites whose activity is aberrantly upregulated in 80-90% of tumors. EGFR antennary-fucosylated glycans have been shown to suppress EGFR dimerization and signaling in lung adenocarcinoma. High levels of fucosylated glycan epitopes have also been observed in OSCC, but invasive regions lose expression of linkage-specific fucosylated epitopes, suggesting that certain fucosylated glycans are involved in the suppression of cell growth and invasion. We found that EGFR from metastatic HSC-3 cells has low levels of fucosylated N-glycans, while EGFR from non-metastatic CAL27 cells shows higher levels of fucosylation at multiple EGFR glycosylation sites including sites N420 and N579, via nUPLC-MS/MS. In cell culture and in mouse tumor xenografts, treatment with ICG-001, a small molecule inhibitor of the interaction between nuclear -catenin and CREB-binding protein (CBP) resulted in higher expression of FUT2 and FUT3, higher fucosylation of EGFR at sites N420 and N579, and decreased EGFR abundance. In addition, we have performed in-depth characterization of multiply-fucosylated N-glycans via glycopeptide tandem mass spectrometry to understand which fucosylated glycan epitopes are involved in the observed effect.
ReviewLevelPeer-reviewed dataset
DatasetOriginOriginal dataset
RepositorySupportUnsupported dataset by repository
PrimarySubmitterKevin Chandler
SpeciesList scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationListiodoacetamide derivatized residue
InstrumentOrbitrap Fusion Lumos; 6550 iFunnel Q-TOF LC/MS; Q Exactive
Dataset History
RevisionDatetimeStatusChangeLog Entry
02020-01-10 03:58:46ID requested
12020-03-26 02:41:04announced
Publication List
Chandler KB, Alamoud KA, Stahl VL, Nguyen BC, Kartha VK, Bais MV, Nomoto K, Owa T, Monti S, Kukuruzinska MA, Costello CE, β-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma. Mol Omics, ():(2020) [pubmed]
Keyword List
submitter keyword: Human, LC-MS/MS, EGFR, epidermal growth factor receptor, OSCC, oral squamous cell carcinoma, head and neck cancer, CAL27, HSC-3, beta-catenin/CBP inhibition, CREB-binding protein, glycopeptide, glycoproteomics
Contact List
Catherine E Costello
contact affiliationCenter for Biomedical Mass Spectrometry Boston University School of Medicine 670 Albany St, Rm 511 Boston, MA 02118-2646 USA
contact emailcecmsms@bu.edu
lab head
Kevin Chandler
contact affiliationBoston University School of Medicine
contact emailchandler64@gmail.com
dataset submitter
Full Dataset Link List
Dataset FTP location
PRIDE project URI
Repository Record List
[ + ]